Astrazeneca Pharma India Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹729 Cr +30.4% YoYSee revenue, profit and what management said. You are viewing Q1 FY19.
AP

Astrazeneca Pharma India Ltd

Q1 FY19Pharmaceuticals & Biotechnology

Astrazeneca Pharma India Q1 FY19: Revenue ₹584.24 Cr

Q1 FY19 investor presentation: what the company reported on revenue, margins and capex.

Astrazeneca Pharma India Ltd Q1 FY19 key numbers

Revenue
Total revenue for AstraZeneca Pharma India Ltd (FY 2017-2018) reported as ₹584.24 Crore.

As stated in Astrazeneca Pharma India Ltd's Q1 FY19 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Astrazeneca Pharma India Ltd's Q1 FY19 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹6,591
Market cap₹16.9K Cr
P/E97.3

The short version

Total revenue for AstraZeneca Pharma India Ltd (FY 2017-2018) reported as ₹584.24 Crore (Page 8).

From Astrazeneca Pharma India Ltd's Q1 FY19 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Total revenue for AstraZeneca Pharma India Ltd (FY 2017-2018) reported as ₹584.24 Crore (Page 8).
  • Partner contribution to sales: ₹29.95 Crore (Page 8).
  • The Indian Pharmaceutical Market (IPM) size is ₹127,253 Crore, poised to grow at ~10% over next four years (Page 6).
  • AstraZeneca is one of the fastest-growing major MNCs in the IPM with 64% contribution from growth platforms (Page 8).

2 more points from Astrazeneca Pharma India Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Astrazeneca Pharma India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Astrazeneca Pharma India Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Astrazeneca Pharma India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Astrazeneca Pharma India Ltd said on order book & pipeline — free account, 30 seconds.

Astrazeneca Pharma India Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹729 Cr, net profit ₹62 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Astrazeneca Pharma India Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Astrazeneca Pharma India Ltd Q1 FY19 results?

Total revenue for AstraZeneca Pharma India Ltd (FY 2017-2018) reported as ₹584.24 Crore (Page 8).

What is Astrazeneca Pharma India Ltd share price analysis?

Astrazeneca Pharma India Ltd currently shows a neutral. The stock trades at a P/E of 97.3 with a market cap of ₹16,879 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Astrazeneca Pharma India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.